MARKET

CARA

CARA

Cara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.73
+0.23
+1.31%
Closed 16:41 07/08 EDT
OPEN
17.53
PREV CLOSE
17.50
HIGH
17.91
LOW
17.34
VOLUME
400.45K
TURNOVER
--
52 WEEK HIGH
27.55
52 WEEK LOW
8.88
MARKET CAP
829.69M
P/E (TTM)
-6.9652
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CARA stock price target is 33.13 with a high estimate of 40.00 and a low estimate of 19.00.

EPS

CARA News

More
Is Cara Therapeutics Inc (CARA) A Good Stock To Buy?
Insider Monkey · 16h ago
Heavy upside, catalysts ahead in liver disease space for Needham
Seeking Alpha - Article · 06/30 21:52
Top Marijuana Stocks for July 2020
Investopedia · 06/30 19:16
Top Marijuana Stocks on the NASDAQ for July 2020
Investopedia · 06/30 19:07
Top Marijuana Stocks for July 2020
The marijuana industry is made up of companies that either support or are engaged in the research, development, distribution, and sale of medical and recreational marijuana. Many big marijuana companies have continued to post sizable net losses as they focus
Investopedia · 06/30 18:16
Top Marijuana Stocks on the NASDAQ for July 2020
The marijuana industry includes companies directly related to the research, development, and distribution of cannabis products, as well as companies that indirectly support these operations. As a growing number of U.S. states and countries around the world le
Investopedia · 06/30 18:07
Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A.
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced the appointment of S
GlobeNewswire · 06/30 11:00
Better Buy: GW Pharmaceuticals vs. Cara Therapeutics
MotleyFool.com · 06/28 18:36

Industry

Biotechnology & Medical Research
+1.13%
Pharmaceuticals & Medical Research
+0.50%

Hot Stocks

Symbol
Price
%Change

About CARA

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.
More

Webull offers kinds of Cara Therapeutics Inc stock information, including NASDAQ:CARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CARA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CARA stock methods without spending real money on the virtual paper trading platform.